A Republican congressman told the head of the Food and Drug Administration (FDA) on Wednesday that the agency’s failure to enact regulations for CBD is one of several problems that is “disrupting public confidence” in its abilities.
Rep. Andy Harris (R-MD) said during a House Appropriations subcommittee hearing that “controversies swirl around the agency.” One of those controversies is the fact that FDA hasn’t identified a “regulatory pathway for cannabidiol oil after five years and millions of dollars of investments.”
Harris, a vocal opponent of marijuana legalization who chairs the subcommittee, told FDA Commissioner Robert Califf that there’s a “need to quickly remedy what is not working in the agency, institute needed reforms and restore public confidence.”
Califf did not offer a direct response to Harris’s comments on CBD at the hearing.
FDA announced in January that it will not be creating rules to allow the marketing of CBD as dietary supplements or food items, leaving the massive industry without regulations despite repeated calls for administrative action from lawmakers, advocates and stakeholders.
Following a “careful review” of the non-intoxicating cannabinoid, FDA said it reached the conclusion that the existing regulatory pathways that are in place for other
Read full article on Marijuana Moment
